Affini-T Therapeutics
Vision
Powering T cells to cure solid tumors.
Approach
Affini-T is unlocking the power of T cells and targeting core oncogenic drivers to develop potentially curative therapies for solid tumor cancers. Our differentiated cell therapy platform harnesses state-of-the-art engineering, and synthetic biology capabilities to target even the most devastating cancer-driving mutations, beginning with KRAS. We leverage these tools to optimize T-cell functions and rewrite the rules of the solid tumor microenvironment, enabling the potential for sustained clinical outcomes in patients. Building on the world-class innovation inherent in our leadership team, founders and technologies, we are powered to develop transformational medicines that last.
Affini-T Therapeutics is addressing
CEO:
Jak Knowles, MD (Co-Founder and CEO)
Founders:
Phil Greenberg, M.D. (Scientific Co-founder)
Aude Chapuis, M.D. (Scientific Co-founder)
Tom Schmitt, Ph.D. (Scientific Co-founder)
Arjun Goyal M.D., M.Phil. (Co-founder)
Vida Ventures (Co-founder)
First investment:
March 2022